INTRODUCTION: Although neoadjuvant chemoradiotherapy (CRT) is the standard treatment for advanced rectal cancer (RC), markers predicting response have not been adequately defined. PATIENTS AND METHODS: In 73 cases with advanced RC, we evaluated the tumor response with the reduction rate of the longitudinal size of RC using barium enema image taken before and after CRT. Then, we retrospectively examined the association with various blood values taken before CRT. The tumor size reduction rate was significantly greater in ten CR cases than in 63 non-CR cases (p < 0.001). RESULTS: Interestingly, the size reduction ratio was positively associated with hemoglobin, albumin level and lymphocyte percentage in leukocytes, while being negatively associated with platelet counts, C-reactive protein and fibrinogen levels as well as neutropliles percentage. Moreover, high lymphocyte counts (>1,800/mm(3)) had an independent association with disease-free survival. CONCLUSIONS: Blood data have a major impact on the tumor response to CRT. Control of host condition may improve the effectiveness of CRT in advanced RC.
INTRODUCTION: Although neoadjuvant chemoradiotherapy (CRT) is the standard treatment for advanced rectal cancer (RC), markers predicting response have not been adequately defined. PATIENTS AND METHODS: In 73 cases with advanced RC, we evaluated the tumor response with the reduction rate of the longitudinal size of RC using barium enema image taken before and after CRT. Then, we retrospectively examined the association with various blood values taken before CRT. The tumor size reduction rate was significantly greater in ten CR cases than in 63 non-CR cases (p < 0.001). RESULTS: Interestingly, the size reduction ratio was positively associated with hemoglobin, albumin level and lymphocyte percentage in leukocytes, while being negatively associated with platelet counts, C-reactive protein and fibrinogen levels as well as neutropliles percentage. Moreover, high lymphocyte counts (>1,800/mm(3)) had an independent association with disease-free survival. CONCLUSIONS: Blood data have a major impact on the tumor response to CRT. Control of host condition may improve the effectiveness of CRT in advanced RC.
Authors: Hee Chul Park; Nora A Janjan; Tito R Mendoza; Edward H Lin; Saroj Vadhan-Raj; Mandeep Hundal; Yiqun Zhang; Marc E Delclos; Christopher H Crane; Prajnan Das; Xin Shelley Wang; Charles S Cleeland; Sunil Krishnan Journal: Int J Radiat Oncol Biol Phys Date: 2009-02-21 Impact factor: 7.038
Authors: Ruud P M Dings; Melissa Loren; Hanke Heun; Elizabeth McNiel; Arjan W Griffioen; Kevin H Mayo; Robert J Griffin Journal: Clin Cancer Res Date: 2007-06-01 Impact factor: 12.531
Authors: Edyta Wolny-Rokicka; Katarzyna Brzeźniakiewicz-Janus; Jerzy Wydmański; Andrzej Tukiendorf; Agnieszka Zembroń-Łacny Journal: J Int Med Res Date: 2018-03-19 Impact factor: 1.671